Retrieve available abstracts of 87 articles: HTML format
Single Articles
September 2025
LIU K, Hoover AR, Sun Y, Valerio TI, et al Anti-tumor effects on tumor-infiltrating natural killer cells by localized
ablative immunotherapy and immune checkpoint inhibitors: An integrated and
comparative study using scRNAseq analysis.
Cancer Lett. 2025;627:217825. PubMedAbstract available
July 2025
RUPP B, Nagpal N, Thanasiu B, Tuck K, et al Multiplex characterization of circulating tumor cells from ductal carcinoma in
situ patients suggests early tumor dissemination.
Cancer Lett. 2025;623:217703. PubMedAbstract available
June 2025
HAYKAL MM, Rodrigues-Ferreira S, El Botty R, Sourd L, et al Targeting WEE1 kinase as a therapeutic strategy in ATIP3-deficient breast
cancers.
Cancer Lett. 2025;620:217665. PubMedAbstract available
WANG W, Yang H, Passang T, Li Y, et al Targeting the VIP-VPAC Pathway in Melanoma Models Inhibits Tumor Growth and Liver
Metastasis.
Cancer Lett. 2025 Jun 5:217855. doi: 10.1016/j.canlet.2025.217855. PubMedAbstract available
May 2025
WU R, Yu S, Bi A, Li Y, et al Therapeutic targeting of circTNK2 with nanoparticles restores tamoxifen
sensitivity and enhances NK cell-mediated immunity in ER-positive breast cancer.
Cancer Lett. 2025 May 24:217823. doi: 10.1016/j.canlet.2025.217823. PubMedAbstract available
ELAYAPILLAI SP, Dogra S, Hladik C, Lausen J, et al Preferential Release of microRNAs via Extracellular Vesicles is Associated with
Ductal Carcinoma In Situ to Invasive Breast Cancer Progression.
Cancer Lett. 2025 May 17:217794. doi: 10.1016/j.canlet.2025.217794. PubMedAbstract available
ZUO WJ, Ma LX, Wang ZH, Cao XC, et al Efficacy and safety of inetetamab plus pertuzumab and nab-paclitaxel as
neoadjuvant therapy for HER2+ breast cancer: A single-arm multicenter phase II
clinical trial.
Cancer Lett. 2025 May 10:217785. doi: 10.1016/j.canlet.2025.217785. PubMedAbstract available
LIU S, Chen H, Gagea M, Federico L, et al ADAMs contribute to triple negative breast cancer via mTORC1 pathway: targeting
ADAM-mTOR axis improves efficacy.
Cancer Lett. 2025 May 6:217775. doi: 10.1016/j.canlet.2025.217775. PubMedAbstract available
JIANG C, Qian Y, Bai X, Li S, et al SLC7A5/E2F1/PTBP1/PKM2 axis mediates progression and therapy effect of
triple-negative breast cancer through the crosstalk of amino acid metabolism and
glycolysis pathway.
Cancer Lett. 2025;617:217612. PubMedAbstract available
April 2025
GRIMSLEY HE, Antczak M, Reddin IG, Weiler N, et al Using a novel panel of drug-resistant triple-negative breast cancer cell lines to
identify candidate therapeutic targets and biomarkers.
Cancer Lett. 2025 Apr 27:217754. doi: 10.1016/j.canlet.2025.217754. PubMedAbstract available
TANG R, Xu X, Yang W, Yu W, et al Corrigendum to "MED27 promotes melanoma growth by targeting AKT/MAPK and
NF/kappaB/iNOS signaling pathway" [Cancer Lett. 373(1) (2016) 77-87 PMID 26797421].
Cancer Lett. 2025;623:217717. PubMed
XIE Y, Xie J, Huang G, Zhang J, et al Isoliquiritigenin reduces brain metastasis by circNAV3-ST6GALNAC5-EGFR axis in
triple negative breast cancer.
Cancer Lett. 2025 Apr 21:217734. doi: 10.1016/j.canlet.2025.217734. PubMedAbstract available
TIAN H, Chen Y, Dong X, Fan X, et al The m(6)A hypermethylation-induced PIR overexpression regulates H3K4me3 and
promotes Tumorigenesis of Uveal Melanoma.
Cancer Lett. 2025 Apr 17:217729. doi: 10.1016/j.canlet.2025.217729. PubMedAbstract available
KUNDU M, Greer YE, Lobanov A, Ridnour L, et al TRAIL induces cytokine production via the NFkB2 pathway promoting neutrophil
chemotaxis and neutrophil-mediated immune-suppression in triple negative breast
cancer cells.
Cancer Lett. 2025;620:217692. PubMedAbstract available
March 2025
LI H, Chatla S, Liu X, Tian Z, et al ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated
cancer cells through activation of homologous recombination.
Cancer Lett. 2025;613:217505. PubMedAbstract available
UEMOTO Y, Lin CA, Wang B, Ye D, et al Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast
cancer with FGFR1/2 alterations.
Cancer Lett. 2025;619:217668. PubMedAbstract available
HOSSAIN SM, Gimenez G, Stockwell P, Weeks R, et al Pre-treatment DNA methylome and transcriptome profiles correlate with melanoma
response to anti-PD1 immunotherapy.
Cancer Lett. 2025 Mar 13:217638. doi: 10.1016/j.canlet.2025.217638. PubMedAbstract available
WANG Z, He K, Liu M, Lv W, et al Enhanced mitochondrial biogenesis facilitates the development of cutaneous
squamous cell carcinoma.
Cancer Lett. 2025 Mar 10:217623. doi: 10.1016/j.canlet.2025.217623. PubMedAbstract available
YOU X, Hu X, Sun Z, Xu W, et al Dual targeting PPARalpha and NPC1L1 metabolic vulnerabilities blocks tumorigenesis.
Cancer Lett. 2025;612:217493. PubMedAbstract available
GILON-ZALTSMAN O, Weidenfeld-Barenboim K, Samara H, Feuermann Y, et al Targeting dormant disseminated tumor cells and their permissive niche by
pro-resolving mediators derived from resolution-phase macrophages.
Cancer Lett. 2025;612:217468. PubMedAbstract available
February 2025
MARRANCI A, Maresca L, Lodovichi S, Luserna di Rora AG, et al PARP1 in Melanoma: Mechanistic Insights and Implications for Basic and Clinical
Research.
Cancer Lett. 2025 Feb 28:217599. doi: 10.1016/j.canlet.2025.217599. PubMedAbstract available
ZENG Z, Yi Z, Xu B The biological and technical challenges facing utilizing circulating tumor DNA in
non-metastatic breast cancer patients.
Cancer Lett. 2025 Feb 19:217574. doi: 10.1016/j.canlet.2025.217574. PubMedAbstract available
CHEN H, Lin L, Qiao Z, Pei Y, et al YTHDF3 drives tumor growth and metastasis by recruiting eIF4B to promote Notch2
translation in breast cancer.
Cancer Lett. 2025;614:217534. PubMedAbstract available
URZI O, Olofsson Bagge R, Crescitelli R Extracellular vesicles in uveal melanoma - biological roles and diagnostic value.
Cancer Lett. 2025 Feb 4:217531. doi: 10.1016/j.canlet.2025.217531. PubMedAbstract available
January 2025
ZHANG R, Jiang WJ, Zhao S, Kang LJ, et al FOXF2 expression triggered by endocrine therapy orchestrates therapeutic
resistance through reorganization of chromatin architecture in breast cancer.
Cancer Lett. 2025 Jan 17:217463. doi: 10.1016/j.canlet.2025.217463. PubMedAbstract available
TAN N, Xia C, Yan X, Cao M, et al Extending breast cancer screening beyond age 45-64 years in China: a
cost-effectiveness analysis.
Cancer Lett. 2025 Jan 13:217457. doi: 10.1016/j.canlet.2025.217457. PubMedAbstract available
November 2024
MUGHAL MJ, Zhang Y, Li Z, Zhou S, et al TFAP2C-DDR1 Axis Regulates Resistance to CDK4/6 Inhibitor in Breast Cancer.
Cancer Lett. 2024 Nov 25:217356. doi: 10.1016/j.canlet.2024.217356. PubMedAbstract available
GERRATANA L, Davis AA, Foffano L, Reduzzi C, et al Integrating Machine Learning-Predicted Circulating Tumor Cells (CTCs) and
circulating tumor DNA (ctDNA) in Metastatic Breast Cancer: a proof of principle
study on endocrine resistance profiling.
Cancer Lett. 2024 Nov 20:217325. doi: 10.1016/j.canlet.2024.217325. PubMedAbstract available
TRAPPETTI V, Fernandez-Palomo C, Arora P, Potez M, et al "Towards melanoma in situ vaccination with multiple ultra-narrow X-ray beams".
Cancer Lett. 2024 Nov 13:217326. doi: 10.1016/j.canlet.2024.217326. PubMedAbstract available
LIU K, Hoover AR, Wang L, Sun Y, et al Localized ablative immunotherapy enhances antitumor immunity by modulating the
transcriptome of tumor-infiltrating Gamma delta T cells.
Cancer Lett. 2024;604:217267. PubMedAbstract available
October 2024
BHATTARAI PY, Kim G, Lim SC, Choi HS, et al METTL3-STAT5B interaction facilitates the co-transcriptional m(6)A modification
of mRNA to promote breast tumorigenesis.
Cancer Lett. 2024;603:217215. PubMedAbstract available
September 2024
YU L, Wei W, Lv J, Lu Y, et al FABP4-mediated lipid metabolism promotes TNBC progression and breast cancer stem
cell activity.
Cancer Lett. 2024 Sep 19:217271. doi: 10.1016/j.canlet.2024.217271. PubMedAbstract available
WINNARD PT JR, Vesuna F, Bol GM, Gabrielson KL, et al Targeting RNA Helicase DDX3X with a Small Molecule Inhibitor for Breast Cancer
Bone Metastasis Treatment.
Cancer Lett. 2024 Sep 19:217260. doi: 10.1016/j.canlet.2024.217260. PubMedAbstract available
LIU X, Ma Z, Jing X, Wang G, et al The deubiquitinase OTUD5 stabilizes SLC7A11 to promote progression and reduce
paclitaxel sensitivity in triple-negative breast cancer.
Cancer Lett. 2024 Sep 12:217232. doi: 10.1016/j.canlet.2024.217232. PubMedAbstract available
CHICA-PARRADO MR, Kim GM, Uemoto Y, Napolitano F, et al Combined inhibition of CDK4/6 and AKT is highly effective against the luminal
androgen receptor (LAR) subtype of triple negative breast cancer.
Cancer Lett. 2024 Sep 5:217219. doi: 10.1016/j.canlet.2024.217219. PubMedAbstract available
ZHANG Z, Zhao M, Wang Q, Wang X, et al Forkhead box protein FOXK1 disrupts the circadian rhythm to promote breast
tumorigenesis in response to insulin resistance.
Cancer Lett. 2024;599:217147. PubMedAbstract available
August 2024
GAO Q, Li N, Pan Y, Chu P, et al Hepatocyte growth factor promotes melanoma metastasis through ubiquitin-specific
peptidase 22-mediated integrins upregulation.
Cancer Lett. 2024 Aug 31:217196. doi: 10.1016/j.canlet.2024.217196. PubMedAbstract available
SRIVASTAVA P, Jha S, Singh SK, Vyas H, et al Protease activated receptor-1 regulates mixed lineage kinase-3 to drive
triple-negative breast cancer tumorigenesis.
Cancer Lett. 2024;603:217200. PubMedAbstract available
MA Y, Zhang H, Shen X, Yang X, et al Aptamer functionalized hypoxia-potentiating agent and hypoxia-inducible factor
inhibitor combined with hypoxia-activated prodrug for enhanced tumor therapy.
Cancer Lett. 2024;598:217102. PubMedAbstract available
LIU B, Liu Y, Yang S, Ye J, et al Enhanced desmosome assembly driven by acquired high-level desmoglein-2 promotes
phenotypic plasticity and endocrine resistance in ER(+) breast cancer.
Cancer Lett. 2024;600:217179. PubMedAbstract available
GU T, Vasilatos SN, Yin J, Qin Y, et al Restoration of TFPI2 by LSD1 Inhibition Suppresses Tumor Progression and
Potentiates Antitumor Immunity in Breast Cancer.
Cancer Lett. 2024 Aug 16:217182. doi: 10.1016/j.canlet.2024.217182. PubMedAbstract available
VIDANA GAMAGE HE, Albright ST, Smith AJ, Farmer R, et al Development of NR0B2 as a therapeutic target for the re-education of tumor
associated myeloid cells.
Cancer Lett. 2024;597:217086. PubMedAbstract available
VIDANA GAMAGE HE, Shahoei SH, Wang Y, Jacquin E, et al NR0B2 re-educates myeloid immune cells to reduce regulatory T cell expansion and
progression of breast and other solid tumors.
Cancer Lett. 2024;597:217042. PubMedAbstract available
REGUA AT, Bindal S, Najjar MK, Zhuang C, et al Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib
suppresses the growth and metastasis of HER2-positive and triple-negative breast
cancers.
Cancer Lett. 2024;597:217023. PubMedAbstract available
YANG Y, Hao X, Zhang J, Gao T, et al The E3 ligase TRIM22 functions as a tumor suppressor in breast cancer by
targeting CCS for proteasomal degradation to inhibit STAT3 signaling.
Cancer Lett. 2024 Aug 8:217157. doi: 10.1016/j.canlet.2024.217157. PubMedAbstract available
FLETCHER K, Cortellini A, Ganta T, Kankaria R, et al Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients
80 years or older: A retrospective cohort study.
Cancer Lett. 2024;596:217001. PubMedAbstract available
KIM YJ, Lee M, Kim EH, Lee S, et al Real-world incidences and risk factors of immune-related adverse events in
patients treated with immune checkpoint inhibitors: A nationwide retrospective
cohort study.
Cancer Lett. 2024;596:216998. PubMedAbstract available
July 2024
LI M, Zhang L, Guan T, Huang L, et al Energy stress-activated AMPK phosphorylates Snail1 and suppresses its stability
and oncogenic function.
Cancer Lett. 2024;595:216987. PubMedAbstract available
LIU Y, Yin S, Lu G, Du Y, et al The intersection of the nervous system and breast cancer.
Cancer Lett. 2024;598:217132. PubMedAbstract available
LIU M, Zhao Z, Wang C, Sang S, et al Harnessing genetic interactions for prediction of immune checkpoint inhibitors
response signature in cancer cells.
Cancer Lett. 2024;594:216991. PubMedAbstract available
ZHANG H, Zhang L, He Y, Jiang D, et al PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive
breast cancer.
Cancer Lett. 2024 Jul 8:217112. doi: 10.1016/j.canlet.2024.217112. PubMedAbstract available
FU Z, Zhang L, Chen R, Zhan J, et al Biphasic co-detection of melanoma aneuploid tumor cells and tumor endothelial
cells in guidance of specifying the field cancerized surgical excision margin and
administering immunotherapy.
Cancer Lett. 2024;598:217099. PubMedAbstract available
June 2024
LIAO Q, Shi H, Yang J, Ge S, et al FTO elicits tumor neovascularization in cancer-associated fibroblasts through
eliminating m(6)A modifications of multiple pro-angiogenic factors.
Cancer Lett. 2024;592:216911. PubMedAbstract available
WAN YX, Qi XW, Lian YY, Liu ZY, et al Electroacupuncture Facilitates Vascular Normalization by Inhibiting Glyoxalase1
in Endothelial Cells to Attenuate Glycolysis and Angiogenesis in Triple-Negative
Breast Cancer.
Cancer Lett. 2024 Jun 28:217094. doi: 10.1016/j.canlet.2024.217094. PubMedAbstract available
YU Y, Cao WM, Cheng F, Shi Z, et al FOXK2 amplification promotes breast cancer development and chemoresistance.
Cancer Lett. 2024 Jun 18:217074. doi: 10.1016/j.canlet.2024.217074. PubMedAbstract available
LIU J, Zhai M, Chen Y, Wei Y, et al Acetylation-dependent deubiquitinase USP26 stabilizes BAG3 to promote breast
cancer progression.
Cancer Lett. 2024 Jun 14:217005. doi: 10.1016/j.canlet.2024.217005. PubMedAbstract available
WANG S, Xu L, Wang D, Zhao S, et al YTHDF1 promotes the osteolytic bone metastasis of breast cancer via inducing EZH2
and CDH11 translation.
Cancer Lett. 2024 Jun 11:217047. doi: 10.1016/j.canlet.2024.217047. PubMedAbstract available
LI SY, Zhang N, Zhang H, Wang N, et al Deciphering the TCF19/miR-199a-5p/SP1/LOXL2 pathway: Implications for breast
cancer metastasis and epithelial-mesenchymal transition.
Cancer Lett. 2024;597:216995. PubMedAbstract available
ANDRIANI L, Ling YX, Yang SY, Zhao Q, et al Sideroflexin-1 promotes progression and sensitivity to lapatinib in
triple-negative breast cancer by inhibiting the TOLLIP-mediated autophagic
degradation of CIP2A.
Cancer Lett. 2024 Jun 5:217008. doi: 10.1016/j.canlet.2024.217008. PubMedAbstract available
OLUWALANA D, Adeleye KL, Krutilina RI, Chen H, et al Biological activity of a stable 6-aryl-2-benzoyl-pyridine colchicine-binding site
inhibitor, 60c, in metastatic, triple-negative breast cancer.
Cancer Lett. 2024 Jun 5:217011. doi: 10.1016/j.canlet.2024.217011. PubMedAbstract available
RIVERA-RAMOS A, Cruz-Hernandez L, Talaveron R, Sanchez-Montero MT, et al Galectin-3 depletion tames pro-tumoural microglia and restrains cancer cells
growth.
Cancer Lett. 2024;591:216879. PubMedAbstract available
May 2024
SONG Y, Ren S, Chen X, Li X, et al Inhibition of MFN1 restores tamoxifen-induced apoptosis in resistant cells by
disrupting aberrant mitochondrial fusion dynamics.
Cancer Lett. 2024;590:216847. PubMedAbstract available
LV Y, Sun S, Zhang J, Wang C, et al Loss of RBM45 inhibits breast cancer progression by reducing the SUMOylation of
IRF7 to promote IFNB1 transcription.
Cancer Lett. 2024 May 24:216988. doi: 10.1016/j.canlet.2024.216988. PubMedAbstract available
WANG J, Hirose H, Du G, Chong K, et al Corrigendum to "P-REX1 amplification promotes progression of cutaneous
melanomavia the PAK1/P38/MMP-2 pathway" [Cancer Lett. 407 (2017) 66-75].
Cancer Lett. 2024 May 23:216966. doi: 10.1016/j.canlet.2024.216966. PubMed
LIN Z, Chen L, Wang Y, Zhang T, et al Improving Ultrasound Diagnostic Precision for Breast Cancer and Adenosis with
Modality-Specific Enhancement (MSE) - Breast Net.
Cancer Lett. 2024 May 23:216977. doi: 10.1016/j.canlet.2024.216977. PubMedAbstract available
BELLI S, Esposito D, Ascione CM, Messina F, et al EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and
CDK4/6 inhibitors in ER+ breast cancer.
Cancer Lett. 2024 May 22:216968. doi: 10.1016/j.canlet.2024.216968. PubMedAbstract available
April 2024
ZHANG Y, Tan Y, Yuan J, Tang H, et al circLIFR-007 reduces liver metastasis via promoting hnRNPA1 nuclear export and
YAP phosphorylation in breast cancer.
Cancer Lett. 2024;592:216907. PubMedAbstract available
JIA Y, Zhang F, Meng X, Andreev D, et al Osteocytes support bone metastasis of melanoma cells by CXCL5.
Cancer Lett. 2024 Apr 6:216866. doi: 10.1016/j.canlet.2024.216866. PubMedAbstract available
WANG L, Liu X, Han Y, Tsai HI, et al TRAF6 enhances PD-L1 expression through YAP1-TFCP2 signaling in melanoma.
Cancer Lett. 2024 Apr 5:216861. doi: 10.1016/j.canlet.2024.216861. PubMedAbstract available
LI K, Lin H, Liu A, Qiu C, et al SOD1-high fibroblasts derived exosomal miR-3960 promotes cisplatin resistance in
triple-negative breast cancer by suppressing BRSK2-mediated phosphorylation of
PIMREG.
Cancer Lett. 2024;590:216842. PubMedAbstract available
WANG J, Fan P, Shen P, Fan C, et al XBP1s activates METTL3/METTL14 for ER-phagy and paclitaxel sensitivity regulation
in breast cancer.
Cancer Lett. 2024 Apr 4:216846. doi: 10.1016/j.canlet.2024.216846. PubMedAbstract available
ORHAN E, Velazquez C, Tabet I, Fenou L, et al CDK inhibition results in pharmacologic BRCAness increasing sensitivity to
olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer.
Cancer Lett. 2024 Apr 2:216820. doi: 10.1016/j.canlet.2024.216820. PubMedAbstract available
BULLOCK KK, Shattuck-Brandt R, Scalise C, Luo W, et al Endogenous pAKT activity is associated with response to AKT inhibition alone and
in combination with immune checkpoint inhibition in murine models of TNBC.
Cancer Lett. 2024;586:216681. PubMedAbstract available
March 2024
YANG Z, Chen H, Yin S, Mo H, et al PGR-KITLG signaling drives a tumor-mast cell regulatory feedback to modulate
apoptosis of breast cancer cells.
Cancer Lett. 2024 Mar 29:216795. doi: 10.1016/j.canlet.2024.216795. PubMedAbstract available
IDRISS MH, Stull CM, Migden MR Treatments on the horizon for locally advanced basal cell carcinoma.
Cancer Lett. 2024;589:216821. PubMedAbstract available
JABBARZADEH KABOLI P, Chen HF, Babaeizad A, Roustai Geraylow K, et al Unlocking c-MET: A comprehensive journey into targeted therapies for breast
cancer.
Cancer Lett. 2024 Mar 8:216780. doi: 10.1016/j.canlet.2024.216780. PubMedAbstract available
MADORSKY ROWDO FP, Xiao G, Khramtsova GF, Nguyen J, et al Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are
sensitive to synergistic combination PARP inhibitor treatment.
Cancer Lett. 2024;584:216608. PubMedAbstract available
February 2024
WANG X, Deng X, Hu J, Zheng W, et al K48-linked deubiquitination of VGLL4 by USP15 enhances the efficacy of tumor
immunotherapy in triple-negative breast cancer.
Cancer Lett. 2024 Feb 29:216764. doi: 10.1016/j.canlet.2024.216764. PubMedAbstract available
SUN J, Du R, Li X, Liu C, et al CD63(+) cancer-associated fibroblasts confer CDK4/6 inhibitor resistance to
breast cancer cells by exosomal miR-20.
Cancer Lett. 2024 Feb 23:216747. doi: 10.1016/j.canlet.2024.216747. PubMedAbstract available
HAN BY, Chen C, Luo H, Lin CJ, et al Clinical sequencing defines the somatic and germline mutation landscapes of
Chinese HER2-Low Breast Cancer.
Cancer Lett. 2024 Feb 23:216763. doi: 10.1016/j.canlet.2024.216763. PubMedAbstract available
MURTHY D, Dutta D, Attri KS, Samanta T, et al CD24 negativity reprograms mitochondrial metabolism to PPARalpha and NF-kappaB-driven
fatty acid beta-oxidation in triple-negative breast cancer.
Cancer Lett. 2024 Feb 17:216724. doi: 10.1016/j.canlet.2024.216724. PubMedAbstract available
XIONG H, Zhai Y, Meng Y, Wu Z, et al Acidosis activates breast cancer ferroptosis through ZFAND5/SLC3A2 signaling axis
and elicits M1 macrophage polarization.
Cancer Lett. 2024 Feb 13:216732. doi: 10.1016/j.canlet.2024.216732. PubMedAbstract available
BAHREYNI A, Mohamud Y, Luo H Oncolytic virus-based combination therapy in breast cancer.
Cancer Lett. 2024 Feb 1:216634. doi: 10.1016/j.canlet.2024.216634. PubMedAbstract available
TAN Z, Boyapati K, Tressler CM, Jenkinson N, et al Glutamine transporter SLC38A3 promotes breast cancer metastasis via
Gsk3beta/beta-catenin/EMT pathway.
Cancer Lett. 2024 Feb 1:216653. doi: 10.1016/j.canlet.2024.216653. PubMedAbstract available
January 2024
CHEN SY, Zhang FL, Zhang YL, Liao L, et al Spermatid perinuclear RNA-binding protein promotes UBR5-mediated proteolysis of
Dicer to accelerate triple-negative breast cancer progression.
Cancer Lett. 2024 Jan 25:216672. doi: 10.1016/j.canlet.2024.216672. PubMedAbstract available
LIU C, Qian X, Yu C, Xia X, et al Inhibition of ATM promotes PD-L1 expression by activating JNK/c-Jun/TNF-alpha
signaling axis in triple-negative breast cancer.
Cancer Lett. 2024 Jan 24:216642. doi: 10.1016/j.canlet.2024.216642. PubMedAbstract available
JIA F, Sun S, Li J, Wang W, et al Neoadjuvant chemotherapy-induced remodeling of human hormonal receptor-positive
breast cancer revealed by single-cell RNA sequencing.
Cancer Lett. 2024 Jan 22:216656. doi: 10.1016/j.canlet.2024.216656. PubMedAbstract available